citric acid, anhydrous has been researched along with Prostatic Neoplasms in 99 studies
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was undertaken to determine respective associations between prostatic citrate or metabolic atrophy (no detectable citrate, choline, and creatine) at magnetic resonance spectroscopy (MRS) and time on hormone-deprivation therapy, serum PSA, and biopsy Gleason score." | 3.74 | Magnetic resonance spectroscopy in patients with locally confined prostate cancer: association of prostatic citrate and metabolic atrophy with time on hormone deprivation therapy, PSA level, and biopsy Gleason score. ( Kurhanewicz, J; Mueller-Lisse, UG; Swanson, MG; Vigneron, DB, 2007) |
| " The (choline + creatine)/ citrate values in regions of histologically confirmed benign prostatic hyperplasia (0." | 3.69 | Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. ( Carroll, PR; Hricak, H; Kurhanewicz, J; Nelson, SJ; Parivar, F; Shinohara, K; Vigneron, DB, 1996) |
| "Twenty-three prostate cancer patients were studied with a combined DCE-MRI and MRSI protocol." | 2.71 | Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. ( Barentsz, JO; de la Rosette, JJ; Engelbrecht, MR; Heerschap, A; Rijpkema, M; van der Graaf, M; van Dorsten, FA; van Leenders, GJ; Verhofstad, A, 2004) |
| "1H spectra from prostate cancer patients were correlated with pathologic areas identified on T2-weighted endorectal coil magnetic resonance (MR) images and histologic study of the step-sectioned gland after surgery." | 2.68 | Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. ( Hricak, H; Konety, B; Kurhanewicz, J; MacDonald, JM; Narayan, P; Nelson, SJ; Vigneron, DB, 1995) |
| "Prostate cancer is the most prevalent cancer in the Western male population and the second leading cause of cancer death in men, affecting over 10 million individuals." | 2.46 | Novel biomarkers and therapeutic targets for prostate cancer. ( Naz, RK; Williams, RM, 2010) |
| "When MRS and MR imaging agree on prostate cancer presence, the positive predictive value is about 80-90%." | 2.44 | Proton MR spectroscopy of the prostate. ( Mueller-Lisse, UG; Scherr, MK, 2007) |
| " Also, an understanding of interacting effects of confounding factors on the absorption, assimilation, and bioavailability of supplemental dietary zinc is important." | 2.43 | Zinc and prostate cancer: a critical scientific, medical, and public interest issue (United States). ( Bagasra, O; Costello, LC; Feng, P; Franklin, RB; Tan, M, 2005) |
| "One of significant characteristics of prostate cancer is slow glycolysis and low FDG avidity." | 2.43 | Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. ( Liu, Y, 2006) |
| "In the design of prostate cancer chemoprevention trials there is a clear need for improved patient selection and risk stratification, as well as the use of biomarkers that could provide earlier assessment of therapeutic efficacy." | 2.41 | Magnetic resonance imaging and spectroscopic imaging: Improved patient selection and potential for metabolic intermediate endpoints in prostate cancer chemoprevention trials. ( Kurhanewicz, J; Swanson, MG; Vigneron, DB; Wood, PJ, 2001) |
| "Robust biomarkers that identify prostate cancer patients with high risk of recurrence will improve personalised cancer care." | 1.46 | Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy. ( Bathen, TF; Berge, V; Bertilsson, H; Braadland, PR; Eri, LM; Euceda, LR; Giskeødegård, G; Grytli, HH; Guldvik, IJ; Hansen, AF; Katz, B; Nygård, S; Sandsmark, E; Selnæs, KM; Svindland, A; Taskén, KA; Tessem, MB, 2017) |
| "Forty-six prostate cancer patients were scanned at 3T." | 1.46 | Quantification of metabolite concentrations in benign and malignant prostate tissues using 3D proton MR spectroscopic imaging. ( Ahlström, H; Häggman, M; Ladjevardi, S; Ortiz-Nieto, F; Tolf, A; von Below, C; Wassberg, C; Weis, J, 2017) |
| "Fifty-seven prostate cancer patients underwent an MR examination followed by prostatectomy." | 1.43 | Contribution of Histopathologic Tissue Composition to Quantitative MR Spectroscopy and Diffusion-weighted Imaging of the Prostate. ( Bruggink, CC; Hambrock, T; Heerschap, A; Hulsbergen-van de Kaa, CA; Kobus, T; Maas, MC; Scheenen, TW; van der Laak, JA, 2016) |
| "The strategy is applied to a prostate cancer patient cohort where data from MR spectroscopy and gene expression have been collected from and integrated on the exact same tissue samples." | 1.43 | A Balanced Tissue Composition Reveals New Metabolic and Gene Expression Markers in Prostate Cancer. ( Angelsen, A; Bathen, TF; Bertilsson, H; Drabløs, F; Rye, MB; Tessem, MB, 2016) |
| "The aim of the present work was to design a pH-modified solid dispersion (pH(M)-SD) that can improve the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug." | 1.40 | Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug: preparation, characterization and evaluation in vivo. ( Fan, Y; Gao, C; Ge, Z; Gong, W; He, S; Huang, X; Shan, L; Tong, Y; Wang, Y; Yang, M, 2014) |
| "Separating indolent from aggressive prostate cancer is an important clinical challenge for identifying patients eligible for active surveillance, thereby reducing the risk of overtreatment." | 1.39 | Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness. ( Angelsen, A; Bathen, TF; Bertilsson, H; Giskeødegård, GF; Gribbestad, IS; Halgunset, J; Selnæs, KM; Tessem, MB; Viset, T; Wright, AJ, 2013) |
| "Prostate cancer is the second leading cause of cancer deaths among men." | 1.37 | Human prostate cancer ZIP1/zinc/citrate genetic/metabolic relationship in the TRAMP prostate cancer animal model. ( Bok, R; Costello, LC; Feng, P; Franklin, RB; Kurhanewicz, J; Swanson, MG; Zou, J, 2011) |
| "Thirty-eight patients with prostate cancer (PCa) and thirty-three patients with benign prostate hyperplasia (BPH) were included in this study." | 1.36 | 1H-MRSI of prostate cancer: the relationship between metabolite ratio and tumor proliferation. ( Gao, ZQ; Liu, JG; Liu, ZQ; Niu, QL; Sun, ZK; Wang, B; Wang, XZ; Yuan, YX, 2010) |
| "In 14 prostate cancer patients who had a final pathologic Gleason scores of i) (3 + 4 = 7, n = 7) and ii) (4 + 3 = 7, n = 7), the metabolite ratios (mean +/- SD) of (Cho + Cr)/Cit and (Cho + Cr)/Spm were calculated using the 2D JPRESS spectra as follows: i) (1." | 1.36 | Correlation of endorectal 2D JPRESS findings with pathological Gleason scores in prostate cancer patients. ( Gomez, AM; Margolis, DJ; McClure, T; Nagarajan, R; Raman, SS; Thomas, MA, 2010) |
| "Time-intensity curves were obtained for prostatic cancer and healthy PZ and CG from DCE-MRI." | 1.35 | Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience. ( Bonanno, E; Carlani, M; Finazzi Agrò, E; Mancino, S; Simonetti, G, 2008) |
| "It has been shown that in metastatic prostate cancer, the amount of citrate in prostatic fluid is significantly reduced, approaching the level normally found in blood." | 1.33 | Expression of Na+-dependent citrate transport in a strongly metastatic human prostate cancer PC-3M cell line: regulation by voltage-gated Na+ channel activity. ( Brackenbury, WJ; Djamgoz, MB; Mycielska, ME; Palmer, CP, 2005) |
| "There is now convincing evidence that prostate cancer cells lack the ability to produce and accumulate citrate." | 1.32 | Deformable image registration for the use of magnetic resonance spectroscopy in prostate treatment planning. ( Dibiase, SJ; Gullapalli, R; Wu, X; Yu, CX, 2004) |
| "Four well-established human prostate cancer cell lines were therefore studied with magnetic resonance spectroscopy to compare differences in metabolic content with tumor biological behavior." | 1.29 | In vitro proton magnetic resonance spectroscopy of four human prostate cancer cell lines. ( Cornel, EB; de Ruijter, JE; Debruyne, FM; Heerschap, A; Oosterhof, GO; Schalken, JA; Smits, GA, 1995) |
| "An estimate of the spatial extent of prostate cancer was determined by generating metabolite images in which this metabolite ratio significantly exceeded normal peripheral zone values in multiple contiguous sections." | 1.29 | Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. ( Carroll, P; Hricak, H; Kurhanewicz, J; Narayan, P; Nelson, SJ; Vigneron, DB, 1996) |
| "Cell strains derived from prostate cancers tended to have smaller amounts of citrate than those from normal prostate epithelium." | 1.28 | In vitro proton spectroscopy of normal and abnormal prostate. ( Peehl, D; Sommer, G; Yacoe, ME, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (7.07) | 18.7374 |
| 1990's | 18 (18.18) | 18.2507 |
| 2000's | 34 (34.34) | 29.6817 |
| 2010's | 33 (33.33) | 24.3611 |
| 2020's | 7 (7.07) | 2.80 |
| Authors | Studies |
|---|---|
| Rajalakshmi, K | 1 |
| Deng, T | 1 |
| Muthusamy, S | 1 |
| Xie, M | 1 |
| Xie, J | 1 |
| Lee, KB | 1 |
| Xu, Y | 1 |
| Jupin, M | 1 |
| van Heijster, FHA | 2 |
| Heerschap, A | 9 |
| Breukels, V | 1 |
| Jansen, KCFJ | 1 |
| Schalken, JA | 2 |
| Afshary, H | 1 |
| Amiri, M | 2 |
| Marken, F | 1 |
| McKeown, NB | 1 |
| Yun, KI | 1 |
| Pak, UG | 1 |
| Han, TS | 1 |
| Jo, CM | 1 |
| Sonu, KS | 1 |
| Ri, HG | 1 |
| Bader, DA | 1 |
| McGuire, SE | 1 |
| Fan, X | 1 |
| Zhou, J | 1 |
| Yan, X | 1 |
| Bi, X | 1 |
| Liang, J | 1 |
| Lu, S | 1 |
| Luo, L | 1 |
| Zhou, D | 1 |
| Yin, Z | 1 |
| Braadland, PR | 1 |
| Giskeødegård, G | 1 |
| Sandsmark, E | 1 |
| Bertilsson, H | 5 |
| Euceda, LR | 1 |
| Hansen, AF | 1 |
| Guldvik, IJ | 1 |
| Selnæs, KM | 2 |
| Grytli, HH | 1 |
| Katz, B | 1 |
| Svindland, A | 1 |
| Bathen, TF | 3 |
| Eri, LM | 1 |
| Nygård, S | 1 |
| Berge, V | 1 |
| Taskén, KA | 1 |
| Tessem, MB | 5 |
| Mycielska, ME | 5 |
| Dettmer, K | 1 |
| Rümmele, P | 2 |
| Schmidt, K | 1 |
| Prehn, C | 1 |
| Milenkovic, VM | 2 |
| Jagla, W | 1 |
| Madej, GM | 1 |
| Lantow, M | 1 |
| Schladt, M | 1 |
| Cecil, A | 1 |
| Koehl, GE | 1 |
| Eggenhofer, E | 1 |
| Wachsmuth, CJ | 1 |
| Ganapathy, V | 2 |
| Schlitt, HJ | 1 |
| Kunzelmann, K | 1 |
| Ziegler, C | 1 |
| Wetzel, CH | 2 |
| Gaumann, A | 1 |
| Lang, SA | 1 |
| Adamski, J | 1 |
| Oefner, PJ | 1 |
| Geissler, EK | 2 |
| Klupczynska, A | 1 |
| Plewa, S | 1 |
| Sytek, N | 1 |
| Sawicki, W | 1 |
| Dereziński, P | 1 |
| Matysiak, J | 1 |
| Kokot, ZJ | 1 |
| Abarghoei, S | 1 |
| Fakhri, N | 1 |
| Borghei, YS | 1 |
| Hosseini, M | 1 |
| Ganjali, MR | 1 |
| Giskeødegård, GF | 1 |
| Wright, AJ | 3 |
| Viset, T | 2 |
| Halgunset, J | 2 |
| Angelsen, A | 4 |
| Gribbestad, IS | 2 |
| Weis, J | 3 |
| Ortiz-Nieto, F | 3 |
| Ahlström, H | 3 |
| Sarkar, BK | 1 |
| Chakraborty, C | 1 |
| Sharma, AR | 1 |
| Bae, KJ | 1 |
| Sharma, G | 1 |
| Doss, GP | 1 |
| Dutta, D | 1 |
| Ding, S | 1 |
| Ganbold, B | 1 |
| Nam, JS | 1 |
| Lee, SS | 1 |
| Zbýň, Š | 1 |
| Krššák, M | 1 |
| Memarsadeghi, M | 1 |
| Gholami, B | 1 |
| Haitel, A | 1 |
| Weber, M | 1 |
| Helbich, TH | 1 |
| Trattnig, S | 1 |
| Moser, E | 1 |
| Gruber, S | 1 |
| Yang, M | 1 |
| He, S | 1 |
| Fan, Y | 1 |
| Wang, Y | 1 |
| Ge, Z | 1 |
| Shan, L | 1 |
| Gong, W | 1 |
| Huang, X | 1 |
| Tong, Y | 1 |
| Gao, C | 1 |
| Basharat, M | 1 |
| Payne, GS | 2 |
| Morgan, VA | 2 |
| Parker, C | 1 |
| Dearnaley, D | 1 |
| deSouza, NM | 2 |
| Kobus, T | 2 |
| van der Laak, JA | 1 |
| Maas, MC | 1 |
| Hambrock, T | 2 |
| Bruggink, CC | 1 |
| Hulsbergen-van de Kaa, CA | 2 |
| Scheenen, TW | 4 |
| Drabløs, F | 1 |
| Rye, MB | 1 |
| Kumar, D | 1 |
| Gupta, A | 1 |
| Mandhani, A | 1 |
| Sankhwar, SN | 1 |
| Roberts, MJ | 1 |
| Yaxley, JW | 1 |
| Coughlin, GD | 1 |
| Gianduzzo, TR | 1 |
| Esler, RC | 1 |
| Dunglison, NT | 1 |
| Chambers, SK | 1 |
| Medcraft, RJ | 1 |
| Chow, CW | 1 |
| Schirra, HJ | 1 |
| Richards, RS | 1 |
| Kienzle, N | 1 |
| Lu, M | 1 |
| Brereton, I | 1 |
| Samaratunga, H | 1 |
| Perry-Keene, J | 1 |
| Payton, D | 1 |
| Oyama, C | 1 |
| Doi, SA | 1 |
| Lavin, MF | 1 |
| Gardiner, RA | 1 |
| von Below, C | 1 |
| Tolf, A | 1 |
| Wassberg, C | 1 |
| Häggman, M | 2 |
| Ladjevardi, S | 1 |
| Bellomo, G | 1 |
| Marcocci, F | 1 |
| Bianchini, D | 1 |
| Mezzenga, E | 1 |
| D'Errico, V | 1 |
| Menghi, E | 1 |
| Zannoli, R | 1 |
| Sarnelli, A | 1 |
| Costello, LC | 10 |
| Franklin, RB | 11 |
| Hlavcak, P | 1 |
| Bergman, A | 1 |
| Brame, RS | 1 |
| Zaider, M | 1 |
| Zakian, KL | 2 |
| Koutcher, JA | 3 |
| Shukla-Dave, A | 2 |
| Reuter, VE | 2 |
| Zelefsky, MJ | 1 |
| Scardino, PT | 2 |
| Hricak, H | 6 |
| Wang, XZ | 1 |
| Wang, B | 1 |
| Gao, ZQ | 1 |
| Liu, JG | 1 |
| Liu, ZQ | 1 |
| Niu, QL | 1 |
| Sun, ZK | 1 |
| Yuan, YX | 1 |
| Patel, A | 2 |
| Rizaner, N | 1 |
| Mazurek, MP | 1 |
| Keun, H | 1 |
| Djamgoz, MB | 3 |
| Near, J | 1 |
| Romagnoli, C | 1 |
| Bartha, R | 1 |
| Nagarajan, R | 1 |
| Gomez, AM | 1 |
| Raman, SS | 1 |
| Margolis, DJ | 1 |
| McClure, T | 1 |
| Thomas, MA | 2 |
| Riches, SF | 1 |
| Sandhu, S | 1 |
| Fisher, C | 1 |
| Germuska, M | 1 |
| Collins, DJ | 1 |
| Thompson, A | 1 |
| Williams, RM | 1 |
| Naz, RK | 1 |
| Kirilova, A | 1 |
| Damyanovich, A | 1 |
| Crook, J | 1 |
| Jezioranski, J | 1 |
| Wallace, K | 1 |
| Pintilie, M | 1 |
| Créhange, G | 2 |
| Parfait, S | 2 |
| Liegard, M | 1 |
| Maingon, P | 2 |
| Ben Salem, D | 1 |
| Cochet, A | 2 |
| Funes de la Vega, M | 1 |
| Cormier, L | 2 |
| Bonnetain, F | 2 |
| Mirjolet, C | 2 |
| Brunotte, F | 2 |
| Walker, PM | 1 |
| Klomp, DW | 2 |
| Arteaga, CS | 1 |
| van Asten, J | 1 |
| Boer, VO | 1 |
| Luijten, PR | 1 |
| García-Martín, ML | 1 |
| Adrados, M | 1 |
| Ortega, MP | 1 |
| Fernández González, I | 1 |
| López-Larrubia, P | 1 |
| Viaño, J | 2 |
| García-Segura, JM | 2 |
| Barentsz, JO | 3 |
| Gauthier, M | 1 |
| Walker, P | 1 |
| Buydens, LM | 1 |
| Lodi, A | 1 |
| Ronen, SM | 1 |
| Zou, J | 3 |
| Feng, P | 3 |
| Bok, R | 1 |
| Swanson, MG | 3 |
| Kurhanewicz, J | 8 |
| Dittrich, R | 1 |
| Kurth, J | 1 |
| Decelle, EA | 1 |
| DeFeo, EM | 1 |
| Taupitz, M | 1 |
| Wu, S | 1 |
| Wu, CL | 1 |
| McDougal, WS | 1 |
| Cheng, LL | 1 |
| Geethanath, S | 1 |
| Baek, HM | 1 |
| Ganji, SK | 1 |
| Ding, Y | 1 |
| Maher, EA | 1 |
| Sims, RD | 1 |
| Choi, C | 1 |
| Lewis, MA | 1 |
| Kodibagkar, VD | 1 |
| Flatberg, A | 1 |
| Gribbestad, I | 1 |
| Selnaes, KM | 1 |
| Wright, A | 1 |
| Yue, K | 1 |
| Marumoto, A | 1 |
| Binesh, N | 1 |
| Kaji, Y | 1 |
| Wada, A | 1 |
| Imaoka, I | 1 |
| Matsuo, M | 1 |
| Terachi, T | 1 |
| Kobashi, Y | 1 |
| Sugimura, K | 1 |
| Fujii, M | 1 |
| Maruyama, K | 1 |
| Takizawa, O | 1 |
| Eberhardt, S | 1 |
| Kleinman, S | 1 |
| Muruganandham, M | 1 |
| Sircar, K | 1 |
| Kattan, MW | 1 |
| COOPER, JF | 3 |
| IMFELD, H | 1 |
| FARID, I | 2 |
| LUTWAK-MANN, C | 2 |
| MARBERGER, H | 1 |
| MARBERGER, E | 1 |
| MANN, T | 1 |
| Kumar, R | 1 |
| Kumar, M | 1 |
| Jagannathan, NR | 1 |
| Gupta, NP | 1 |
| Hemal, AK | 1 |
| Juang, HH | 3 |
| Wu, X | 1 |
| Dibiase, SJ | 1 |
| Gullapalli, R | 1 |
| Yu, CX | 1 |
| van Dorsten, FA | 1 |
| van der Graaf, M | 1 |
| Engelbrecht, MR | 1 |
| van Leenders, GJ | 1 |
| Verhofstad, A | 1 |
| Rijpkema, M | 1 |
| de la Rosette, JJ | 1 |
| Palmer, CP | 2 |
| Brackenbury, WJ | 1 |
| Averna, TA | 2 |
| Kline, EE | 2 |
| Smith, AY | 2 |
| Sillerud, LO | 2 |
| Gambarota, G | 1 |
| Weiland, E | 1 |
| Fütterer, JJ | 1 |
| Tan, M | 1 |
| Bagasra, O | 2 |
| Milon, B | 1 |
| Desouki, MM | 2 |
| Singh, KK | 2 |
| Kajdacsy-Balla, A | 1 |
| Feng, TH | 1 |
| Tsui, KH | 1 |
| Yu, Z | 1 |
| Liu, Y | 1 |
| Mueller-Lisse, UG | 2 |
| Vigneron, DB | 5 |
| Broke-Smith, TP | 1 |
| Beckerman, R | 1 |
| Nastos, T | 1 |
| Erguler, K | 1 |
| Treat, EG | 1 |
| Davis, MS | 1 |
| Hom, JJ | 1 |
| Coakley, FV | 1 |
| Simko, JP | 1 |
| Lu, Y | 1 |
| Qayyum, A | 1 |
| Westphalen, AC | 1 |
| Schmitt, LD | 1 |
| Carroll, PR | 2 |
| Matheson, BK | 1 |
| Adams, JL | 1 |
| Patel, R | 1 |
| Scherr, MK | 1 |
| Carlani, M | 1 |
| Mancino, S | 1 |
| Bonanno, E | 1 |
| Finazzi Agrò, E | 1 |
| Simonetti, G | 1 |
| Sheth, AR | 1 |
| Panse, GT | 1 |
| Nelson, SJ | 3 |
| MacDonald, JM | 2 |
| Konety, B | 1 |
| Narayan, P | 4 |
| Shi, SR | 1 |
| Chaiwun, B | 1 |
| Young, L | 1 |
| Cote, RJ | 1 |
| Taylor, CR | 1 |
| Cornel, EB | 1 |
| Smits, GA | 1 |
| de Ruijter, JE | 1 |
| Oosterhof, GO | 1 |
| Debruyne, FM | 1 |
| Wilman, AH | 1 |
| Allen, PS | 1 |
| Schick, F | 2 |
| Bongers, H | 1 |
| Kurz, S | 1 |
| Jung, WI | 1 |
| Pfeffer, M | 1 |
| Lutz, O | 2 |
| Takeda, M | 1 |
| Katayama, Y | 1 |
| Takahashi, H | 1 |
| Go, H | 1 |
| Tsutsui, T | 1 |
| Nishiyama, T | 1 |
| Sato, S | 1 |
| Nakamura, S | 1 |
| Dahiya, R | 1 |
| Chang, LH | 1 |
| James, TL | 1 |
| Carroll, P | 1 |
| Parivar, F | 1 |
| Shinohara, K | 1 |
| Mulkern, RV | 1 |
| Bowers, JL | 1 |
| Peled, S | 1 |
| Williamson, DS | 1 |
| Liney, GP | 1 |
| Turnbull, LW | 1 |
| Lowry, M | 1 |
| Turnbull, LS | 1 |
| Knowles, AJ | 1 |
| Horsman, A | 1 |
| Straubinger, K | 1 |
| Sánchez-Chapado, M | 1 |
| Ibarburen, C | 1 |
| Angulo, JC | 1 |
| González, J | 1 |
| Rodríguez-Vallejo, JM | 1 |
| Zakian, K | 1 |
| Wood, PJ | 1 |
| Yacoe, ME | 1 |
| Sommer, G | 1 |
| Peehl, D | 1 |
| Makhija, M | 1 |
| Kosuda, S | 1 |
| Kawahara, S | 1 |
| Tamura, K | 1 |
| Saito, K | 1 |
| Kubo, A | 1 |
| Hashimoto, S | 1 |
| Le Goff, JM | 1 |
| Martin, PM | 1 |
| Ojasoo, T | 1 |
| Raynaud, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Trans-Rectal Placement of Prostatic Fiducial Markers Under MR-Guidance in Patients Receiving External Beam Radiotherapy for Prostate Cancer: A Pilot Study[NCT00061347] | Phase 1 | 15 participants (Actual) | Interventional | 2003-05-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for citric acid, anhydrous and Prostatic Neoplasms
| Article | Year |
|---|---|
Tumour metabolism and its unique properties in prostate adenocarcinoma.
Topics: Adenocarcinoma; Cell Proliferation; Citric Acid; Citric Acid Cycle; Glycolysis; Humans; Lipogenesis; | 2020 |
Novel biomarker for prostate cancer diagnosis by MRS.
Topics: Biomarkers, Tumor; Choline; Citric Acid; Creatine; Humans; Inositol; Magnetic Resonance Spectroscopy | 2014 |
Extracellular Citrate in Health and Disease.
Topics: Astrocytes; Biological Transport; Bipolar Disorder; Brain; Cell Membrane; Citric Acid; Dementia; Epi | 2015 |
Prostatic fluid electrolyte composition for the screening of prostate cancer: a potential solution to a major problem.
Topics: Biomarkers, Tumor; Body Fluids; Citric Acid; Early Detection of Cancer; Electrolytes; Humans; Male; | 2009 |
Citrate transport and metabolism in mammalian cells: prostate epithelial cells and prostate cancer.
Topics: Animals; Biological Transport; Cell Membrane; Citric Acid; Cytoplasm; Epithelial Cells; Fatty Acids; | 2009 |
Novel biomarkers and therapeutic targets for prostate cancer.
Topics: Anoctamins; Antigens, Neoplasm; Biomarkers, Tumor; Citric Acid; Endoplasmic Reticulum; Golgi Apparat | 2010 |
Zinc and prostate cancer: a critical scientific, medical, and public interest issue (United States).
Topics: Animals; Cation Transport Proteins; Citric Acid; Dietary Supplements; Gene Expression; Humans; In Si | 2005 |
Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer.
Topics: Carcinoma; Citric Acid; Dietary Fats; Energy Metabolism; Fatty Acids; Humans; Lipid Metabolism; Male | 2006 |
The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots.
Topics: Acetyl Coenzyme A; Cation Transport Proteins; Citric Acid; Genes, Tumor Suppressor; Humans; Magnetic | 2006 |
Proton MR spectroscopy of the prostate.
Topics: Biopsy; Choline; Citric Acid; Creatine; Diagnosis, Differential; Humans; Imaging, Three-Dimensional; | 2007 |
Citrate in the diagnosis of prostate cancer.
Topics: Biomarkers, Tumor; Citric Acid; Humans; Magnetic Resonance Spectroscopy; Male; Neoplasm Staging; Pre | 1999 |
Magnetic resonance spectroscopic studies of the prostate.
Topics: Adenocarcinoma; Choline; Citric Acid; Humans; Magnetic Resonance Spectroscopy; Male; Neoplasm Stagin | 2000 |
The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy.
Topics: Animals; Cell Transformation, Neoplastic; Citric Acid; Citric Acid Cycle; Disease Progression; Epith | 2000 |
Magnetic resonance imaging and spectroscopic imaging: Improved patient selection and potential for metabolic intermediate endpoints in prostate cancer chemoprevention trials.
Topics: Citric Acid; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Neoplasm Pro | 2001 |
3 trials available for citric acid, anhydrous and Prostatic Neoplasms
| Article | Year |
|---|---|
Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol.
Topics: Antigens, Neoplasm; Atorvastatin; Biomarkers, Tumor; Citric Acid; Double-Blind Method; Drug Therapy, | 2016 |
Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer.
Topics: Aged; Citric Acid; Clinical Protocols; Humans; Image Processing, Computer-Assisted; Magnetic Resonan | 2004 |
Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy.
Topics: Adenocarcinoma; Aged; Biomarkers; Case-Control Studies; Citrates; Citric Acid; Diagnosis, Differenti | 1995 |
82 other studies available for citric acid, anhydrous and Prostatic Neoplasms
| Article | Year |
|---|---|
Prostate cancer biomarker citrate detection using triaminoguanidinium carbon dots, its applications in live cells and human urine samples.
Topics: Biomarkers, Tumor; Carbon; Citric Acid; Fluorescent Dyes; Humans; Male; Prostate; Prostatic Neoplasm | 2022 |
Metabolite interactions in prostatic fluid mimics assessed by
Topics: Citrates; Citric Acid; Humans; Inositol; Magnetic Resonance Imaging; Male; Prostatic Neoplasms; Prot | 2022 |
Carbon sources and pathways for citrate secreted by human prostate cancer cells determined by NMR tracing and metabolic modeling.
Topics: Biomarkers, Tumor; Carbon; Carbon Isotopes; Citrates; Citric Acid; Citric Acid Cycle; Glucose; Human | 2022 |
ECL sensor for selective determination of citrate ions as a prostate cancer biomarker using polymer of intrinsic microporosity-1 nanoparticles/nitrogen-doped carbon quantum dots.
Topics: Biomarkers, Tumor; Carbon; Citric Acid; Electrochemical Techniques; Humans; Luminescent Measurements | 2023 |
Determination of prostatic fluid citrate concentration using peroxidase-like activity of a peroxotitanium complex.
Topics: Body Fluids; Citrates; Citric Acid; Early Detection of Cancer; Humans; Male; Peroxidases; Prostatic | 2023 |
Citrate activates autophagic death of prostate cancer cells via downregulation CaMKII/AKT/mTOR pathway.
Topics: Animals; Autophagic Cell Death; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinase Type | 2021 |
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.
Topics: Aged; Biomarkers, Tumor; Citric Acid; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Ne | 2017 |
Extracellular Citrate Affects Critical Elements of Cancer Cell Metabolism and Supports Cancer Development
Topics: Animals; Anion Transport Proteins; Cell Line, Tumor; Cell Proliferation; Citric Acid; Epithelial Cel | 2018 |
A study of low-molecular-weight organic acid urinary profiles in prostate cancer by a new liquid chromatography-tandem mass spectrometry method.
Topics: Chromatography, Liquid; Citric Acid; Energy Metabolism; Gluconates; Humans; Male; Prostatic Neoplasm | 2018 |
A colorimetric paper sensor for citrate as biomarker for early stage detection of prostate cancer based on peroxidase-like activity of cysteine-capped gold nanoclusters.
Topics: Biomarkers, Tumor; Citric Acid; Colorimetry; Cysteine; Gold; Humans; Lab-On-A-Chip Devices; Limit of | 2019 |
Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness.
Topics: Aged; Biomarkers, Tumor; Citric Acid; Disease Progression; Electron Spin Resonance Spectroscopy; Hum | 2013 |
MR spectroscopy of the prostate at 3T: measurements of relaxation times and quantification of prostate metabolites using water as an internal reference.
Topics: Adult; Aged; Biomarkers, Tumor; Body Water; Choline; Citric Acid; Creatine; Humans; Magnetic Resonan | 2013 |
Technical Note: evaluation of the uncertainties in (choline + creatine)/citrate ratios measured by proton MR spectroscopic imaging in patients suspicious for prostate cancer.
Topics: Adult; Aged; Algorithms; Biomarkers, Tumor; Choline; Citric Acid; Creatine; Humans; Magnetic Resonan | 2014 |
Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug: preparation, characterization and evaluation in vivo.
Topics: Animals; Animals, Inbred Strains; Antineoplastic Agents; Biological Availability; Cinnamates; Citric | 2014 |
TE = 32 ms vs TE = 100 ms echo-time (1)H-magnetic resonance spectroscopy in prostate cancer: Tumor metabolite depiction and absolute concentrations in tumors and adjacent tissues.
Topics: Aged; Algorithms; Biomarkers, Tumor; Citric Acid; Humans; Magnetic Resonance Imaging; Male; Prostati | 2015 |
Contribution of Histopathologic Tissue Composition to Quantitative MR Spectroscopy and Diffusion-weighted Imaging of the Prostate.
Topics: Biomarkers, Tumor; Choline; Citric Acid; Creatine; Diffusion Magnetic Resonance Imaging; Humans; Ima | 2016 |
A Balanced Tissue Composition Reveals New Metabolic and Gene Expression Markers in Prostate Cancer.
Topics: Biomarkers, Tumor; Citric Acid; Cohort Studies; Fatty Acids; Gene Expression Regulation, Neoplastic; | 2016 |
NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics.
Topics: Aged; Biomarkers, Tumor; Biopsy; Citric Acid; Diagnosis, Differential; Digital Rectal Examination; G | 2016 |
Quantification of metabolite concentrations in benign and malignant prostate tissues using 3D proton MR spectroscopic imaging.
Topics: Aged; Biomarkers, Tumor; Choline; Citric Acid; Humans; Imaging, Three-Dimensional; Male; Middle Aged | 2017 |
MR Spectroscopy in Prostate Cancer: New Algorithms to Optimize Metabolite Quantification.
Topics: Algorithms; Choline; Citric Acid; Creatine; Humans; Magnetic Resonance Spectroscopy; Male; Phantoms, | 2016 |
Two-dimensional spectroscopic imaging for pretreatment evaluation of prostate cancer: comparison with the step-section histology after radical prostatectomy.
Topics: Adult; Aged; Biopsy; Case-Control Studies; Choline; Citric Acid; Creatine; False Negative Reactions; | 2009 |
Regarding the focal treatment of prostate cancer: inference of the Gleason grade from magnetic resonance spectroscopic imaging.
Topics: Algorithms; Biopsy; Choline; Citric Acid; Creatine; Humans; Logistic Models; Magnetic Resonance Spec | 2009 |
1H-MRSI of prostate cancer: the relationship between metabolite ratio and tumor proliferation.
Topics: Aged; Aged, 80 and over; Algorithms; Biomarkers, Tumor; Choline; Citric Acid; Creatine; Diagnosis, C | 2010 |
Reduced power magnetic resonance spectroscopic imaging of the prostate at 4.0 Tesla.
Topics: Adult; Biomarkers, Tumor; Choline; Citric Acid; Creatine; Electromagnetic Fields; Humans; Magnetic R | 2009 |
Correlation of endorectal 2D JPRESS findings with pathological Gleason scores in prostate cancer patients.
Topics: Aged; Choline; Citric Acid; Creatine; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Pr | 2010 |
MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters.
Topics: Aged; Area Under Curve; Choline; Citric Acid; Contrast Media; Gadolinium DTPA; Humans; Image Interpr | 2009 |
3D MR-spectroscopic imaging assessment of metabolic activity in the prostate during the PSA "bounce" following 125iodine brachytherapy.
Topics: Brachytherapy; Choline; Citric Acid; Creatine; Humans; Iodine Radioisotopes; Magnetic Resonance Imag | 2011 |
Tumor volume and metabolism of prostate cancer determined by proton magnetic resonance spectroscopic imaging at 3T without endorectal coil reveal potential clinical implications in the context of radiation oncology.
Topics: Aged; Biomarkers, Tumor; Choline; Citric Acid; Creatine; Humans; Magnetic Resonance Spectroscopy; Ma | 2011 |
Detection of fully refocused polyamine spins in prostate cancer at 7 T.
Topics: Biomarkers, Tumor; Choline; Citric Acid; Creatine; Humans; Magnetic Resonance Spectroscopy; Male; Po | 2011 |
Quantitative (1) H MR spectroscopic imaging of the prostate gland using LCModel and a dedicated basis-set: correlation with histologic findings.
Topics: Adenocarcinoma; Choline; Citric Acid; Creatine; Humans; In Vitro Techniques; Magnetic Resonance Spec | 2011 |
In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Choline; Citric Acid; Creatine; Equipment Design; Humans; Ma | 2011 |
Early choline levels from 3-tesla MR spectroscopy after exclusive radiation therapy in patients with clinically localized prostate cancer are predictive of plasmatic levels of PSA at 1 year.
Topics: Aged; Androgen Antagonists; Body Water; Chemotherapy, Adjuvant; Choline; Citric Acid; Humans; Magnet | 2011 |
A phase and frequency alignment protocol for 1H MRSI data of the prostate.
Topics: Algorithms; Choline; Citric Acid; Computer Simulation; Creatine; Databases, Factual; Humans; Magneti | 2012 |
Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment.
Topics: Antineoplastic Agents; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Citric Acid; Female; Human | 2011 |
Human prostate cancer ZIP1/zinc/citrate genetic/metabolic relationship in the TRAMP prostate cancer animal model.
Topics: Adenocarcinoma; Animals; Cation Transport Proteins; Citric Acid; Disease Models, Animal; Genetic The | 2011 |
Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Citric Acid; Disease Progression; Epithelium; Humans; Magnetic Resonance Spectroscopy; | 2012 |
Compressive sensing could accelerate 1H MR metabolic imaging in the clinic.
Topics: Algorithms; Analysis of Variance; Aspartic Acid; Brain Neoplasms; Choline; Citric Acid; Creatine; Da | 2012 |
Changes in gene transcription underlying the aberrant citrate and choline metabolism in human prostate cancer samples.
Topics: Aconitate Hydratase; ATP Citrate (pro-S)-Lyase; Choline; Choline Kinase; Citric Acid; Gene Expressio | 2012 |
Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer -- investigation of a correlation with Gleason score.
Topics: Aged; Aged, 80 and over; Choline; Citric Acid; Creatine; Humans; Magnetic Resonance Spectroscopy; Ma | 2013 |
2D JPRESS of human prostates using an endorectal receiver coil.
Topics: Adult; Biomarkers, Tumor; Choline; Citric Acid; Creatine; Humans; Magnetic Resonance Spectroscopy; M | 2002 |
Proton two-dimensional chemical shift imaging for evaluation of prostate cancer: external surface coil vs. endorectal surface coil.
Topics: Adult; Aged; Choline; Citric Acid; Creatine; Humans; Magnetic Resonance Imaging; Magnetic Resonance | 2002 |
Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results.
Topics: Choline; Citric Acid; Creatine; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; | 2003 |
The role of citric acid in the physiology of the prostate: a preliminary report.
Topics: Citrates; Citric Acid; Humans; Hypertrophy; Male; Prostate; Prostatic Hyperplasia; Prostatic Neoplas | 1958 |
The role of citric acid in the physiology of the prostate. A chromatographic study of citric acid cycle intermediates in benign and malignant prostatic tissue.
Topics: Citric Acid; Citric Acid Cycle; Humans; Male; Prostate; Prostatic Neoplasms | 1963 |
CITRIC ACID IN METASTASIZING CARCINOMA OF THE PROSTATE GLAND.
Topics: Carcinoma; Citrates; Citric Acid; Humans; Male; Metabolism; Neoplasm Metastasis; Neoplasms; Prostati | 1963 |
THE ROLE OF CITRIC ACID IN THE PHYSIOLOGY OF THE PROSTATE. 3. LACTATE/CITRATE RATIOS IN BENIGN AND MALIGNANT PROSTATIC HOMOGENATES AS AN INDEX OF PROSTATIC MALIGNANCY.
Topics: Chromatography; Citrates; Citric Acid; Citric Acid Cycle; Humans; Lactates; Lactic Acid; Male; Metab | 1964 |
Citric acid in human prostatic secretion and metastasizing cancer of prostate gland.
Topics: Adenocarcinoma; Citrates; Citric Acid; Humans; Male; Neoplasms; Prostatic Neoplasms | 1962 |
Proton magnetic resonance spectroscopy with a body coil in the diagnosis of carcinoma prostate.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Choline; Citric Acid; Creatine; Diagnosis, Differential; | 2004 |
Modulation of mitochondrial aconitase on the bioenergy of human prostate carcinoma cells.
Topics: Aconitate Hydratase; Adenosine Triphosphate; Cell Division; Citric Acid; Citric Acid Cycle; Cloning, | 2004 |
Deformable image registration for the use of magnetic resonance spectroscopy in prostate treatment planning.
Topics: Algorithms; Citric Acid; Feasibility Studies; Humans; Magnetic Resonance Spectroscopy; Male; Prostat | 2004 |
Cyclic adenosine 3',5'-monosphosphate mediate prolactin regulation of mitochondrial aconitase in human prostate carcinoma cells.
Topics: Aconitate Hydratase; Carcinoma; Cell Line; Citric Acid; Cyclic AMP; Gene Expression Regulation, Neop | 2004 |
Expression of Na+-dependent citrate transport in a strongly metastatic human prostate cancer PC-3M cell line: regulation by voltage-gated Na+ channel activity.
Topics: Carrier Proteins; Cell Line, Tumor; Citric Acid; Gene Expression; Humans; Hydrogen-Ion Concentration | 2005 |
A decrease in 1H nuclear magnetic resonance spectroscopically determined citrate in human seminal fluid accompanies the development of prostate adenocarcinoma.
Topics: Adenocarcinoma; Adult; Citric Acid; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Pros | 2005 |
Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3T.
Topics: Choline; Citric Acid; Computer Simulation; Humans; Magnetic Resonance Spectroscopy; Male; Phantoms, | 2005 |
hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer.
Topics: Cation Transport Proteins; Cell Line, Tumor; Citric Acid; Down-Regulation; Gene Expression Regulatio | 2005 |
Cholesterol modulation of the expression of mitochondrial aconitase in human prostatic carcinoma cells.
Topics: Aconitate Hydratase; Base Sequence; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cholesterol; | 2005 |
EAAC1 is expressed in rat and human prostate epithelial cells; functions as a high-affinity L-aspartate transporter; and is regulated by prolactin and testosterone.
Topics: Animals; Aspartic Acid; Biological Transport; Brain Chemistry; Cell Line, Tumor; Cells, Cultured; Ci | 2006 |
Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues.
Topics: Aconitate Hydratase; Cell Line, Tumor; Citric Acid; Humans; Male; Mitochondria; Prostate; Prostatic | 2006 |
Magnetic resonance spectroscopy in patients with locally confined prostate cancer: association of prostatic citrate and metabolic atrophy with time on hormone deprivation therapy, PSA level, and biopsy Gleason score.
Topics: Aged; Angiogenesis Inhibitors; Atrophy; Biomarkers, Tumor; Biopsy; Choline; Citric Acid; Cross-Secti | 2007 |
Citrate enhances in vitro metastatic behaviours of PC-3M human prostate cancer cells: status of endogenous citrate and dependence on aconitase and fatty acid synthase.
Topics: Aconitate Hydratase; Biological Transport; Cell Adhesion; Cell Line, Tumor; Citric Acid; Cytosol; Fa | 2006 |
Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection.
Topics: Aged; Body Fluids; Citric Acid; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Prostate | 2006 |
High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience.
Topics: Aged; Cell Nucleus; Cell Nucleus Size; Choline; Citric Acid; Cohort Studies; Creatine; Humans; Image | 2007 |
Effect of metabolic inhibitors on ATP and citrate content in PC3 prostate cancer cells.
Topics: Aconitate Hydratase; Adenosine Triphosphate; Antimetabolites; Cell Line, Tumor; Citric Acid; Deoxygl | 2007 |
Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience.
Topics: Aged; Choline; Citric Acid; Contrast Media; Creatine; Gadolinium; Humans; Image Processing, Computer | 2008 |
Can vasectomy reduce the incidence of prostatic tumor?
Topics: Acid Phosphatase; Aged; alpha-Glucosidases; Citrates; Citric Acid; Ejaculation; Humans; Magnesium; M | 1982 |
Bioenergetic theory of prostate malignancy.
Topics: Aconitate Hydratase; Adenosine Triphosphate; Citrates; Citric Acid; Energy Metabolism; Humans; Male; | 1994 |
Antigen retrieval technique utilizing citrate buffer or urea solution for immunohistochemical demonstration of androgen receptor in formalin-fixed paraffin sections.
Topics: Antigens, Neoplasm; Buffers; Carcinoma; Citrates; Citric Acid; Frozen Sections; Humans; Immunoenzyme | 1993 |
In vitro proton magnetic resonance spectroscopy of four human prostate cancer cell lines.
Topics: Androgens; Citrates; Citric Acid; Creatine; Humans; Magnetic Resonance Spectroscopy; Male; Perchlora | 1995 |
Double-quantum filtering of citrate for in vivo observation.
Topics: Adenocarcinoma; Biomarkers, Tumor; Citrates; Citric Acid; Humans; Magnetic Resonance Spectroscopy; M | 1994 |
Localized proton MR spectroscopy of citrate in vitro and of the human prostate in vivo at 1.5 T.
Topics: Citrates; Citric Acid; Humans; In Vitro Techniques; Magnetic Resonance Spectroscopy; Male; Prostate; | 1993 |
[Examination of the risk factors for infectious urolithiasis formation in patients receiving urinary diversion or urinary reconstruction using intestine--comparison of reservoir and ileal conduit].
Topics: Adult; Aged; Calcium Phosphates; Citrates; Citric Acid; Female; Humans; Ileum; Male; Middle Aged; Pr | 1993 |
Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study.
Topics: Adenocarcinoma; Animals; Citrates; Citric Acid; Humans; Magnetic Resonance Spectroscopy; Male; Mice; | 1993 |
Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution.
Topics: Adenocarcinoma; Adult; Aged; Choline; Citrates; Citric Acid; Creatine; Diagnosis, Differential; Huma | 1996 |
Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging.
Topics: Aged; Choline; Citrates; Citric Acid; Creatine; Cryosurgery; Humans; Magnetic Resonance Imaging; Mag | 1996 |
Density-matrix calculations of the 1.5 T citrate signal acquired with volume-localized STEAM sequences.
Topics: Citric Acid; Echo-Planar Imaging; Electron Spin Resonance Spectroscopy; Humans; Image Enhancement; M | 1996 |
In vivo quantification of citrate concentration and water T2 relaxation time of the pathologic prostate gland using 1H MRS and MRI.
Topics: Adenocarcinoma; Aged; Biopsy; Body Water; Citric Acid; Diagnosis, Differential; Humans; Magnetic Res | 1997 |
Influence of pulse angle variations on stimulated echo acquisition mode proton nuclear magnetic resonance spectra of AB spin systems: theory and experiments with citrate.
Topics: Acetic Acid; Citric Acid; Humans; Magnetic Resonance Spectroscopy; Male; Models, Theoretical; Prosta | 1998 |
In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology.
Topics: Aged; Aged, 80 and over; Choline; Citric Acid; Creatine; Diagnosis, Differential; Humans; Inositol; | 1999 |
In vitro proton spectroscopy of normal and abnormal prostate.
Topics: Adenocarcinoma; Carbon; Cells, Cultured; Citrates; Citric Acid; Gas Chromatography-Mass Spectrometry | 1991 |
Metastatic prostatic carcinoma presenting as an anterior mediastinal mass on gallium imaging.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Citrates; Citric Acid; Gallium Radioisotopes; Humans; Male; | 1991 |
Ga-67 uptake in diethylstilbestrol-induced gynecomastia. Experience with six patients.
Topics: Aged; Breast; Citrates; Citric Acid; Diethylstilbestrol; Gallium; Gallium Radioisotopes; Gynecomasti | 1990 |
Non-michaelian behavior of 5 alpha-reductase in human prostate.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Citrates; Citric Acid; Humans; In Vitro Techniques; Kinetics; | 1989 |